From the Institute of Parasitology and
§ Department of Biochemistry, McGill University,
Quebec H9X 3V9, Canada
Received for publication, October 26, 2000, and in revised form, December 26, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
MRP1 is an ABC (or ATP binding cassette) membrane
transport protein shown to confer resistance to structurally dissimilar drugs. Studies of MRP1 topology suggested the presence of a hydrophobic N-domain with five potential membrane-spanning domains linked to an
MDR1-like core (MSD1-NBD1-L1-MSD2-NBD2) by an intracellular linker
domain (L0). MRP1-mediated multidrug resistance is thought to be due to
enhanced drug efflux. However, little is known about MRP1-drug
interaction and its drug binding site(s). We previously developed
several photoreactive probes to study MRP1-drug interactions. In this
report, we have used eight MRP1-HA variants that were modified to have
hemagglutinin A (HA) epitopes inserted at different sites in MRP1
sequence. Exhaustive in-gel digestion of all IAARh123 photoaffinity-labeled MRP1-HA variants revealed the same profile of
photolabeled peptides as seen for wild type MRP1. Photolabeling of the
different MRP1-HA variants followed by digestion with increasing concentrations of trypsin or Staphylococcus aureus V8
protease (1:800 to 1:5 w/w) and immunoprecipitation with anti-HA mAb
identified two small photolabeled peptides (~6-7 kDa) from
MRP1-HA(574) and MRP1-HA(1222). Based on the location of the HA
epitopes in the latter variants together with molecular masses of the
two peptides, the photolabeled amino acid residues were localized to
MRP1 sequences encoding transmembranes 10 and 11 of MSD1
(Ser542-Arg593) and transmembranes 16 and 17 of
MSD2 (Cys1205-Glu1253). Interestingly, the same
sequences in MRP1 were also photolabeled with a structurally different
photoreactive drug, IACI, confirming the significance of
transmembranes 10, 11, 16 and 17 in MRP1 drug binding. Taken together,
the results in this study provide the first delineation of the drug
binding site(s) of MRP1. Furthermore, our findings suggest the presence
of common drug binding site(s) for structurally dissimilar drugs.
Increased expression of P-glycoprotein
(P-gp1)1 or the multidrug
resistance protein (MRP1) has been associated with the rise of drug
resistance in numerous tumor cell lines in vitro (1, 2).
Gene transfer studies have also provided direct correlation between
P-gp1 or MRP1 expression and resistance to dissimilar anti-cancer
drugs; hence, the multidrug resistance (MDR) phenotype. In addition,
gene disruption studies (3, 4) in mice have demonstrate an increased
drug accumulation in MRP1 or P-gp1-expressing tissues and organs.
Interestingly and despite the low level of sequence identity between
MRP1 and P-gp1 (<20% (5)), the two proteins confer resistance to
similar natural product anti-cancer drugs (6). However in contrast to
P-gp1, a distinguishing feature of MRP1 endogenous and exogenous
substrates is their derivatization by glutathione, glucuronate, or
sulfate (7-11). Notably, the cysteinyl leukotriene LTC4 is
the highest affinity substrate and an important modulator of
inflammatory response (9). Other endogenous substrates include
glucuronate- and sulfate-conjugated bile salts, glutathione-conjugated prostaglandin A2, as well as oxidized glutathione (GSSG)
(8, 12, 13).
P-gp1 and MRP1 are members of the ABC (or ATP binding cassette) family
of membrane transport proteins (14) that couple the hydrolysis of ATP
to drug transport. Members of this family contain one or more blocks of
six membrane-spanning domains (MSD) linked to a nucleotide binding
domain (NBD) (14). In contrast to P-gp1, MRP1 encodes for an additional
hydrophobic N-domain with five potential transmembrane sequences (MSD0)
and an extracytoplasmic N terminus (15-18). Consequently, the linear
organization of MRP1 consists of MSD0 linked to an MDR1-like core
(MSD1-NBD1-L1-MSD2-NBD2) through an intracytoplasmic linker domain
(L0). Functional analyses of truncated MRP1 demonstrate that deletion
of the L0 domain abolished MRP1-mediated LTC4 transport,
whereas deletion of the MSD0 while maintaining L0 behaved as the
full-length protein (19, 20).
The mechanism of MRP1-mediated transport is not well understood and
appears to differ from that of P-gp1. Drug transport studies using
P-gp1-expressing plasma membranes clearly demonstrate an energy-dependent transport through direct binding to P-gp1
(21). Likewise, MRP1-mediated transport of LTC4 is
energy-dependent and likely to occur by direct binding to
MRP1 (22). However, transport of unmodified natural product drugs by
MRP1 has been shown to occur in association with glutathione (23-26).
Using several MRP1-specific photoreactive drugs, we have demonstrated
direct binding between MRP1 and unmodified natural product drugs
(27-31). Moreover, glutathione was not required for MRP1-drug
interaction. In addition, proteolysis of IACI- or IAARh123-photolabeled
MRP1 produced three small peptides (27, 28). In this report, we have
mapped the drug binding site(s) of MRP1. To achieve this, we made use
of eight MRP1 variants containing hemagglutinin A (HA) epitopes
inserted at different positions in MRP1 (17, 32). Our results show for
the first time the presence of two major drug binding domains, confined
to ~50 amino acids each and encoding TMs 10-11 and TMs 16-17.
Materials--
Iodine-125 (100.7 mCi/ml) and the Protein
A-coupled Sepharose were purchased from Amersham Pharmacia Biotech. The
monoclonal anti-hemagglutinin A antibody 16B12 (anti-HA) was from the
Berkeley Antibody Co. (Richmond, California). All chemicals were
of the highest commercial grade available.
Cell Culture and Plasma Membrane Preparation--
HeLa cells
transfected with vector alone or MRP1-HA cDNA variants (17, 32)
were used in this study. HeLa-MRP1-HA variants describe cells
expressing MRP1 containing one or more copies of hemagglutinin A
epitope (YPYDVPDYAS) inserted at amino acids 4, 163, 271, 574, 653, 938, 1001, or 1222 from the N terminus of MRP1 (see Fig. 1). Briefly,
cells were grown in Photoaffinity Labeling and Protease Digestion--
Plasma
membranes from HeLa or HeLa-MRP1-HA variants were photoaffinity-labeled
with IAARh123 or IACI photoreactive drugs as previously described (27,
28). Photolabeled MRP1-HA variants were excised from SDS-PAGE and
processed for in-gel digestion with Staphylococcus aureus V8
protease (20 µg/gel slice) according to the method of Cleveland
et al. (34). Alternatively, 100-µg aliquots of
photolabeled plasma membranes were digested with increasing concentrations of trypsin (sequencing grade and TPKC
(L-1-tosylamido-2-phenylethyl chloromethyl ketone)-treated
from Roche Molecular Biochemicals) at 37 °C for 40 min. After
digestion, samples were transferred to ice, and the digestion was
stopped by the addition of 80 µl of buffer A (1% SDS, 0.05 M Tris, pH 7.4) containing protease inhibitors (10 µg/ml
leupeptin, pepstatin A, aprotinin, and 1 mM
phenylmethylsulfonyl fluoride). Samples were left on ice for 15 min and
then diluted with 320 µl of buffer B (1.25% Triton X-100, 190 mM NaCl, 0.05 M Tris, pH 7.4). IAARh123- or
IACI-photolabeled MRP1-HA was immunoprecipitated with anti-HA mAb as
previously described (35).
SDS-PAGE and Western Blotting--
Protein samples were resolved
on SDS-PAGE using the Fairbanks gel system (36). Radiolabeled proteins
were visualized on dried gels after exposure to Kodak X-AR film at
Tumor cells overexpressing MRP1 show reduced sensitivity to
natural product toxins and certain anti-cancer drugs likely due to
enhanced drug clearance (2). However, little is known about MRP1-drug
interaction and binding site(s). Using photoreactive drug analogues, we
have recently demonstrated the photoaffinity labeling of MRP1 at
multiple sites (27, 28). In this study, eight different MRP1-HA
variants (see Fig. 1) were used to
identify the sequences of MRP1 drug binding site(s). The expression and characterization of all eight MRP1-HA variants have been previously described (17, 32), and their function was determined to be similar to
wild type or unmodified MRP1. Fig.
2A shows a Western blot
analysis of membranes from untransfected and MRP1-HA-transfected HeLa
cells probed with anti-HA mAb. With the exception of the MRP1-HA (574),
all other MRP1-HA variants showed high levels of MRP1 (Fig.
2A). To determine whether IAARh123 could photolabel the
MRP1-HA variants, plasma membranes were labeled with IAARh123, and
proteins were either resolved on SDS-PAGE (Fig. 2B) or used for immunoprecipitation with anti-HA mAb (Fig. 2C). Fig.
2B shows an IAARh123-photolabeled ~190-kDa polypeptide in
all 8 membrane samples. Moreover, Fig. 2C confirms the
identity of the labeled protein as MRP1. The lower photoaffinity
labeling signal associated with MRP1-HA (574) is consistent with the
low level of expression seen in plasma membranes from cells expressing
this variant (Fig. 2A). To determine whether the insertion
of HA epitopes at different positions in MRP1 has affected the binding
domains relative to unmodified MRP1, immunopurified
IAARh123-photolabeled MRP1-HA variants were excised from SDS-PAGE gels
and digested with S. aureus V8 protease according to the
method of Cleveland et al. (34). The results in Fig.
2D show the same digestion profile for the labeled MRP1-HA
variants; hence, the insertion of HA epitopes in MRP1 at the specified
positions (Fig. 1) did not affect its drug interaction. Moreover, the
lack of effect of HA epitope insertion on photolabeling characteristics
of MRP1 is in agreement with the lack of effect of HA epitope insertion
on the drug resistance profile in transfectant HeLa cells (17, 32). In
addition, similar results were also obtained using the
quinoline-derived photoreactive drug, IACI (results not shown).
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-minimal essential medium (
MEM)
containing 10% fetal bovine serum (Hyclone). Cells were detached with
trypsin-EDTA and then mixed immediately with cell culture media
containing 20% horse serum followed by several washes in
phosphate-buffered saline solution, pH 7.4. The cell pellets were
resuspended in hypotonic Tris-Mg2+ buffer (1 mM
MgCl2 and 10 mM Tris-HCl, pH 7.0) containing
protease inhibitors (2 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin A) and homogenized in a glass Dounce homogenizer. The
resulting cell homogenate was spun for 10 min at 400 × g, and the resulting supernatant was spun for an additional
60 min at 100,000 × g. Plasma membrane-enriched
pellets were resuspended in 5 mM Tris buffer, pH 7.4, and
washed once to remove residual protease inhibitors. The final membrane
pellets were resuspended in Tris-sucrose buffer (5 mM Tris,
250 mM sucrose, pH 7.4) using a 27-gauge needle and separated into aliquots for storage at
70 °C. Proteins were
quantified using the Lowry assay (33).
80 °C. For immuno-detection of recombinant MRP1-HA variants,
20-µg samples of enriched plasma membranes were resolved on SDS-PAGE
and transferred to nitrocellulose membrane by using a wet
electroblotting technique essentially as outlined by Towbin et
al. (37). Nitrocellulose membranes were blocked in 5% skim milk
in phosphate-buffered saline solution (pH 7.4) and incubated with
anti-HA mAb overnight at 4 °C. Membranes were washed and incubated
with 1:3000 (v/v) of goat anti-mouse antibody conjugated to horseradish
peroxidase. Immunoreactive proteins were visualized by
chemiluminescence using Pierce SuperSignal substrate.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (31K):
[in a new window]
Fig. 1.
Schematic representation of MRP1
topology. MRP1 is thought to encode for 17 putative TMs organized
as MSD0 plus an MDR1-like core (MSD1+NBD1+MSD2+NBD2). The
rectangular bars represent the transmembrane domains of
MRP1. The arrows with numbers show the positions
of the hemagglutinin A (HA) epitope insertions. The
numbers within parentheses refer to the number of
repeats of the HA epitope. The nucleotide binding domains are indicated
as NBD1 and NBD2. The extracellular (OUT) and the
intracellular (IN) sides of the membrane are also
indicated.
View larger version (84K):
[in a new window]
Fig. 2.
Biochemical characterization of the eight
MRP1-HA variants. Plasma membranes from the various
MRP1-HA-transfected HeLa cells were resolved on SDS-PAGE and probed
with anti-HA mAb (panel A), photoaffinity labeled with
IAARh123 (panel B), immunopurified with anti-HA mAb after
photoaffinity labeling by IAARh123 (panel C), and subjected
to in-gel digestion with S. aureus V8 protease (panel
D). The migration of the molecular mass marker proteins is
indicated to the left of the figure.
We have recently shown that MRP1 is photoaffinity-labeled at multiple
sites with two structurally dissimilar drugs (27, 28). Mild proteolytic
cleavage of MRP1 with trypsin generated 111- and 85-kDa
photoaffinity-labeled polypeptides that, respectively, produced two and
one small photolabeled peptides upon further digestion (27, 28). To
achieve a higher resolution map of MRP1 photoaffinity-labeled sites,
plasma membranes from each of the eight MRP1-HA variants were
photoaffinity-labeled, digested with increasing concentrations of
trypsin (1:800-1:5 w/w), and then immunoprecipitated with anti-HA mAb.
Only those polypeptides having an HA epitope and a cross-linked
IAARh123 were utilized in the analyses of MRP1 binding domains. Fig.
3 shows the results of three MRP1-HA
variants in which HA epitopes are inserted at positions 4, 163, and 271 from the N terminus of MRP1. Resolution of anti-HA-immunoprecipitated
tryptic digest showed one polypeptide with a molecular mass of 111 kDa
from MRP1-HA(4), -HA(163), and -HA(271) (Figs. 3, A-C).
Hence, only the 111-kDa fragment contained the IAARh123-labeled
amino acid residue(s) and either one of the three HA epitopes. The
schematic in Fig. 3D shows the three HA epitopes relative to
the trypsin sensitive site in the linker domain (L1). Further digestion
of the 111-kDa polypeptide with trypsin led to the loss of the
IAARh123-photolabeled residue(s) or the HA-epitopes.
|
The 50-kDa photolabeled protein is nonspecifically immunoprecipitated and appears in all the lanes from HeLa and HeLa-HA variants (Fig. 3). Although identity of this 50-kDa photolabeled protein is not known, comparison of photolabeled MRP1 and 50-kDa proteins by Cleveland digestion (34) did not reveal similar photolabeled peptides or peptide maps (results not shown). Interestingly, however, the 50-kDa protein was much less apparent when the IAARh123-photolabeled membranes immunoprecipitated with hybridoma supernatant containing anti-HA mAb was isolated from cells grown in absence of 10% fetal bovine serum. Thus, the presence of serum proteins is likely to be responsible for the nonspecific immunoprecipitation of the 50-kDa protein (results not shown).
Analysis of MRP1-HA variants that have HA epitopes inserted at
positions 574 or 653 from the N terminus is shown in Fig.
4. Proteolytic digestion of
IAARh123-photolabeled membranes with increasing concentrations of
trypsin generated five and three photoaffinity-labeled peptides with
MRP1-HA (574) and -HA (653), respectively (Figs. 4, A and
B). For MRP1-HA (574), five polypeptides with approximate
molecular masses of 111, 44, 31, 23, and 6.5 kDa contained both
IAARh123 photolabel and the HA epitope. Again, relative to the
trypsin-sensitive site in L1 linker domain, the 111-kDa photolabeled
polypeptide encodes sequences that include MSD0, L0, MSD1, and NBD1 as
indicated on the schematic in Fig. 4C. This polypeptide is
rapidly degraded to four smaller peptides with apparent molecular
masses of 44, 31, 23, and 6.5 kDa, representing sequences between the
two trypsin-sensitive sites in L0 and L1 linker domains (Fig.
4C). The 44- and 31-kDa IAARh123-photolabeled peptides were
immunoprecipitated from the digestion products of both MRP1-HA (574)
and -HA (653) variants. Thus, a maximum region of ~280 amino acid
residues contains either HA (574) or HA (653) epitopes as well as the
IAARh123-labeled site(s). Interestingly, further digestion of MRP1-HA
(574) but not MRP1-HA (653), revealed the presence of two smaller
photoaffinity-labeled peptides (23 and 6.5 kDa; Fig. 4A).
The immunoprecipitation of a ~6.5-kDa photolabeled peptide from
MRP1-HA (574), but not from MRP1-HA (653), positions the peptide
between Lys541 (Ser542) and Arg593,
before the HA epitope at amino acid 653. Consequently, the first IAARh123-photolabeled polypeptide encodes 51 amino acids of MRP1 (Ser542-Arg593) plus 10 amino acid residues
from the HA-epitope at position 574 of MRP1 (see Fig. 1).
|
Using three other MRP1-HA variants (938, 1001, and 1222) in which the
HA epitopes are localized between the trypsin-sensitive site in L1 and
the C terminus of MRP1, plasma membranes were photoaffinity-labeled with IAARh123, treated with trypsin, and immunoprecipitated with anti-HA mAb. The results in Fig. 5,
A-C, show two IAARh123-labeled polypeptides
immunoprecipitated from MRP1-HA (938), -HA (1001), and -HA (1222)
tryptic digests migrating with apparent molecular masses of ~130 and
85 kDa. The 85-kDa IAARh123-photolabeled polypeptide has been
previously identified by using epitope-specific mAbs (QRCL-1 and MRPm6
(27, 28)) and encodes MRP1 sequences immediately after the
trypsin-sensitive site in L1 (see schematic in Fig. 5D). The
130-kDa polypeptide represents a cleavage of MRP1 at L0, the second
trypsin-sensitive site (38), and encodes the MDR1-like core
(MSD1-NBD1-L1-MSD2-NBD2; see schematic in Fig. 5D). It
should be mentioned that the same 130-kDa IAARh123-photolabeled polypeptide is observed after immunoprecipitation of tryptic digests from MRP1-HA (574) and -HA (653) but not from MRP1-HA (4), -HA (163),
and -HA (271) variants (Figs. 3 and 4). In contrast to MRP1-HA (938)
and -HA (1001), immunoprecipitation of MRP1-HA (1222) digest showed
four IAARh123 photoaffinity-labeled peptides (Fig. 5): the 130- and
85-kDa polypeptides plus two additional peptides migrating with
molecular masses of 41 and 7 kDa (Fig. 5C). The 41-kDa
photoaffinity-labeled polypeptide encoded MRP1 sequences beyond the
1001 epitope insertion site and is equivalent to ~370 amino acids
toward the C-terminal end of MRP1 (see schematic representation in Fig.
5D). The 7-kDa polypeptide represents the smallest
photolabeled peptide that can be immunoprecipitated from the tryptic
digest of IAARh123 photoaffinity-labeled MRP1-HA (1222) (Fig.
5C). Consequently, the second IAARh123-photolabeled
polypeptide contains sequences between Leu1203 and
Arg1249 of MRP1 (plus 20 amino acid residues of 2 HA-epitopes at position 1222).
|
To ascertain the positions of the IAARh123-photolabeled peptides of
MRP1-HA (574) and -HA (1222) more closely, photolabeled membrane
samples were digested with higher concentrations of trypsin or S. aureus V8 protease (up to 1:5 w/w), and the total digest was
subjected to immunoprecipitation with anti-HA mAb. Fig.
6A shows a photolabeled
peptide derived from the exhaustive digestion of MRP1-HA (574) with
trypsin, migrating with an apparent molecular mass of a ~6.5
kDa. Careful examination of MRP1 amino acid sequence for the smallest
possible tryptic peptide that include the HA epitope at position 574 revealed the following peptide sequence 542SAYLSAVGTFTWVCTPFLVALCTFAVYVTIDEN[HA]NILDAQTAFV SLALFNILR593,
where the underlined sequences represent the predicted TM10 and TM11.
The calculated molecular mass of the photoaffinity-labeled peptide,
including the amino acid sequence of one HA epitopes, is 6.8 kDa.
Exhaustive digestion of IAARh123-photolabeled MRP1-HA (574) variants
with V8 protease followed by immunoprecipitation with anti-HA mAb did
not show any other photolabeled small peptides (data not shown).
Similarly, exhaustive digestion of IAARh123-photolabeled membranes of
MRP1-HA (1222) with V8 protease revealed the presence of a
~7-kDa photolabeled peptide (Fig. 6B). Analysis of MRP1
sequence for all possible V8 peptides that include the HA epitope at
position 1222, revealed the following amino acid sequence
1205
CVGNCIVLFAALFAVISR[HA-HA]HSLSAGLVGLSVSYSLQVTTYLNWLVRMSSE1253,
where the underlined sequences represent the predicted TM16 and TM17.
The calculated molecular mass of this peptide including the amino acid
sequence of the two HA epitopes is ~7.6 kDa.
|
As indicated earlier, we have recently demonstrated that both IAARh123
and IACI, two structurally dissimilar photoreactive drugs, labeled
similar tryptic peptides that migrate with apparent molecular masses of
4-6 kDa on SDS-PAGE (27, 28). Given the localization of IAARh23 drug
binding sites in MRP1, it was of interest to determine the
IACI-photolabeled sequences using the MRP1-HA variants. Fig.
7 shows immunopurified peptides from
IACI-labeled MRP1-HA (574) and -HA (1222) after digestion with trypsin
and V8 protease, respectively. Interestingly, Fig. 7A shows
a ~6.5-kDa IACI-photolabeled peptide immunoprecipitated from MRP1-HA
(574) tryptic digest. Likewise, MRP1-HA (1222) showed an ~7-kDa
IACI-photolabeled peptide (Fig. 7B). Digestion of
IACI-photolabeled plasma membranes prepared from the other MRP1-HA
variants led to identical photolabeled peptides as IAARh123 (data not
shown). Taken together these results demonstrate the binding of two
structurally dissimilar drugs to the same site(s) of MRP1.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Similar to P-gp1, MRP1 is believed to cause resistance to anti-cancer drugs through an enhanced drug clearance mechanism (39). Indeed, there is considerable overlap in substrate specificity to anti-cancer drugs between MRP1 and P-gp1 (39). However, MRP1 also mediates the transport of other normal cell metabolites such as glutathione-, sulfate-, and glucuronate-modified ligands. Furthermore, given the structural differences between MRP1 and P-gp1 and the low sequence identity (<20% (5)), it has been difficult to speculate about the mechanism of MRP1 based on the current understanding of P-gp1-mediated drug transport. For example, unlike P-gp1, it has not been possible to demonstrate direct binding between MRP1 and unmodified natural product drugs, likely due to low binding affinities. Moreover, it remains unclear how reduced glutathione mediates MRP1 drug transport. Using a quinoline-based photoreactive drug, we have previously shown direct interaction between MRP1 and natural product drugs (29-31). Consistent with our findings, Leier et al. (9) also show direct photolabeling of MRP1 by [3H]LTC4. Although it has not been possible to determine which domain(s) in MRP1 interacts directly with LTC4.
Analyses of the first three MRP1-HA(4, 163, and 271) variants using IACI and IAARh123 revealed the presence of only one photolabeled polypeptide with an apparent molecular mass of 111 kDa. Further digestion of the 111-kDa fragment, which contained three HA epitopes at positions 4, 163, or 271 from the N terminus did not produce smaller photolabeled peptides. Therefore, the MRP1 sequence within the first 274 amino acid residues (relative to the position of the first lysine located right after the HA epitope insertion at position 271) are not photolabeled with IAARh123 or IACI. Alternatively, it is possible that the first 274 amino acid residues of MRP1 are photoaffinity-labeled; however, after the addition of higher trypsin concentrations, the photolabeled site was separated from the HA epitope. Although this latter possibility is conceivable with one HA epitope, it is unlikely to occur with all HA epitopes inserted at three different positions in MRP1 (at amino acids 4, 163, and 271 from the N terminus). Moreover, we and others previously demonstrated the presence of two trypsin hypersensitive sites, one in each of the linker domains (L1 and L0) of MRP1, with cleavage at L1 proceeding that at L0 (27, 28, 38). Consequently, cleavage at L1 would generate the 111- and 85-kDa polypeptides followed by a cleavage of the 111-kDa at L0 producing two polypeptides with apparent molecular masses of 40-60 and 60 kDa (16). The 40-60-kDa fragment would include MSD0, whereas the 60-kDa fragment would include MSD1 (16). The absence of photolabeled 40-60-kDa polypeptides with either one of the three MRP1-HA (4, 163, 271) variants is consistent with the lack of drug interactions within the first 274 N-terminal amino acids. These results are consistent with earlier findings whereby deletion of the first N-terminal 203 amino acids behaved like wild-type MRP1 in vesicle uptake of LTC4 (19). Having previously demonstrated that IACI and IAARh123 interacts with MRP1 at the same or an overlapping site(s) as that of LTC4, we speculate that MSD0 does not interact with either drug.
Similar analyses of the other five MRP1-HA (574, 653, 938, 1001, 1222) variants revealed two photolabeled peptides with apparent molecular masses of 6.5 and 7 kDa, derived from MRP1-HA (574) and -HA (1222), respectively. Proteolytic cleavage at L0 of MRP1-HA (574, 653, 938, 1001, 1222) variants produced a common polypeptide with a molecular mass of 130 kDa, consisting of MSD1-NBD1-L1-MSD2-NBD2 (Fig. 1). Cleavage at L1 produced the 111- and 85-kDa fragments form MRP1-HA (574, 653) and MRP1-HA (938, 1001, 1222), respectively. In addition, further proteolytic digestion of MRP1-HA (653) produced two smaller photolabeled peptides (44 and 31 kDa), which encode for MSD1 and some parts of NBD1 (Fig. 4B). In contrast to MRP1-HA (653), similar proteolytic cleavage of MRP1-HA (574) produced two additional photolabeled peptides (23 and 6.5 kDa) that encode TMs 8-11 and TM10-11, respectively. Digestion of MRP1-HA (574) with higher concentrations of trypsin did not result in further cleavage of the 6.5-kDa peptide. Analysis of MRP1 sequence for all potential trypsin cleavage sites near the HA epitope inserted at position 574 of MRP1 revealed the presence of Lys541 and Arg593. Thus cleavage at these positions would produce a 62-amino acid peptide, taking into consideration the 10 residues from the HA insertion (see schematic diagram in Fig. 5C).
Earlier in-gel digestion studies of IACI- or IAARh123-photolabeled 111-kDa fragments, which encodes MSD0-L0-MSD1-NBD1 and parts of L1, showed two photolabeled peptides with apparent molecular masses of ~6 and ~4 kDa (27, 28). Based on the observed results with MRP1-HA (4, 163, 271, 574, 653), which yielded only one photolabeled peptide containing the HA epitope at position 574, the previously observed photolabeled peptides (4 and 6 kDa) may represent incomplete digestion of the photolabeled fragment (Leu536-Glu623) at internal V8 protease cuts at Asp572 or Asp578. Thus, V8 protease cuts at Asp572 or Asp578 would produce a fragment with an estimated molecular mass of ~4 kDa (Leu536 to Asp572/Asp578 or Asp572/Asp578 to Glu623) in addition to an ~6-kDa fragment representing Leu536-Glu623.
Tryptic digestion of MRP1-HA (1222), by contrast to MRP1-HA(938 and 1001), produced two photolabeled peptides (41 and 7 kDa) in addition to the 85-kDa polypeptide (Fig. 5). The 41-kDa photolabeled peptide did not contain the first 1013 N-terminal amino acid residues of MRP1 (relative to the position of the first lysine located right after the HA epitope insertion at position 1001) and is likely to encode part of the MSD2 and NBD2. The second smallest photolabeled peptide produced from the total cleavage of the MRP1-HA (1001) is likely to encode the last two transmembrane domains of MSD2. Analysis of MRP1 amino acid sequence for potential trypsin cuts near the 1222 HA epitope showed three potential sites, Arg1202, Arg1222, and Arg1249. Cleavage at Arg1202 and Arg1249 would generate a 67-amino acid peptide, including the two 10-residue repeats for the HA epitope, with a calculated molecular mass of 7.6 kDa versus an apparent molecular mass of 7 kDa. Interestingly however, exhaustive trypsin digestion of MRP1-HA (1222) variant did not produce a smaller peptide that could represent cleavage at Arg1222. One possibility is that the Arg1222 site was not accessible to trypsin. Alternatively, cleavage at Arg1222 did occur, but the peptide generated from this cleavage was not photolabeled. Consequently, the photolabel is cross-linked to sequences between Arg1202 and Arg1222 or within TM16. The localization of the 7-kDa photolabeled peptide in MRP1-HA (1222) was further confirmed after exhaustive proteolytic digestion with V8 protease, which produced a 7-kDa peptide. Scanning MRP1 sequences for potential V8 sites revealed two glutamate residues (Glu1204 and Glu1253) near HA(1222). Hence the resulting polypeptide of 69 amino acid residues has a calculated molecular mass of 7.5 kDa versus an apparent mass of 7 kDa on SDS-PAGE. The localization of the 7-kDa IAARh123-photolabeled peptide to MRP1 sequences, which include TMs 16 and 17, is consistent with proteolytic cleavage of MRP1 with two different proteases. The latter findings are in agreement with an earlier study suggesting a possible role of the C-terminal domain (MSD2 and NBD2 or residues 959-1531) in determining MRP1 resistance to and transport of anthracyclines (40).
The photolabeling of the same peptides of MRP1 by two structurally dissimilar photoreactive drugs (IAARh123 and IACI) suggests common binding domains. However, given the size of the photolabeled peptides with a combined sequence of 100 amino acid residues, it is conceivable that the photolabeled peptides can encode several binding sites for different groups of compounds. Alternatively, the photolabeled peptides in MRP1 represent domains that are distant from the drug transport site(s). Although the latter possibility is plausible, earlier mapping studies of P-gp1 drug binding site(s) using photoreactive drugs have shown that photoaffinity-labeled sequences represent functionally important drug binding sites, and mutations of amino acids in such domains modulate P-gp1 drug transport (41-43). However, several questions relating to P-gp1 broad substrate specificity and the ability of P-gp1 to accommodate the binding of drugs remain unanswered. The photoaffinity-labeled domains of MRP1, which encode TMs 10-11 and TMs 16-17, are separated by ~400 amino acid residues in its linear sequence (5). As such, photolabeling of MSD1 and MSD2 sequences in MRP1 suggest one of two possibilities; (a) the two photolabeled sequences from MSD1 and MSD2 are brought together by protein folding to form one large binding cavity that can accommodate interactions with many structurally dissimilar drugs or (b) the two photolabeled peptides represent two separate drug binding sites in MSD1 and MSD2 that are allosterically regulated. Although it is not possible to deter mine which model best fits the observed results in the current study, earlier reports with P-gp1 suggested two or more spatially separate sites linked allosterically through protein conformation (44, 45).
Secondary structure predictions of MRP1 have suggested the presence of a hydrophobic domain with five transmembrane domains (MSD0) and an extracytoplasmic N terminus linked to an MDR1-like core consisting of two MSDs and two NBDs in tandem (MSD1-NBD1-MSD2-NBD2). In contrast to MRP1, secondary structure predictions of P-gp1 have suggested two tandemly repeated MSD and NBD or an MDR1-like core. Alignment of the MRP1 and P-gp1 predicted secondary structures revealed TM 5-6 and TM 11-12 of P-gp1 to correspond to TM 10-11 and TM 16-17 of MRP1, respectively. Thus, the drug binding sites of both P-gp1 and MRP1 are localized to parallel domains in both proteins. This finding is unexpected in light of the low sequence identify between the two proteins (<20% (5)). Comparison of the amino acid sequences of the four major transmembrane domains in MRP1 and P-gp1 showed 14, 9, 4, and 14% sequence identity between TM 5, 6, 11, 12 of P-gp1 and TM 10, 11, 16, 17 of MRP1, respectively. In addition, helical wheel presentation of the transmembrane domains did not reveal any obvious similarities between MRP1 and P-gp1 transmembrane sequences.
The findings that the photolabeled sequences of MRP1 encode transmembrane domains is interesting, since similar results have been obtained with P-gp1 whereby TMs 5-6 and 11-12 were also shown to mediate P-gp1-drug interactions (42-45). However, unlike P-gp1, which mediates the transport of hydrophobic drugs mainly from within the lipid bilayer, MRP1 appears to interact with and mediate the transport of drugs from the cytoplasm and the hydrophobic environment of the lipid bilayer (46-48). Consequently, the P-gp1-drug interaction model may be an oversimplified version of MRP1-drug interactions.
In summary, the results of this study have identified two domains in
MRP1 to a resolution of ~50 amino acid residues that are
photoaffinity-labeled with two structurally dissimilar drugs. Moreover,
based on positions of the photolabeled peptides, the results of this
study show that the drug binding domains are localized to TMs 10-11 of
MSD1 and TMs 16-17 of MSD2. Efforts to identify the precise amino acid
residues that are cross-linked to IAARh123 and IACI are ongoing. In
addition, it will be of interest to know if the photolabeled sites
identified in this study are the same or different from the binding
site(s) of normal MRP1 substrates (e.g. LTC4 and
other cell metabolites).
![]() |
FOOTNOTES |
---|
* This work was supported by grants from The Canadian Institutes of Health Research, (to E. G.) and The National Cancer Institute of Canada (to P. G.). Research at the Institute of Parasitology is partially supported by a grant from the Fonds pour la Formation de Chercheurs et l'Aides à la Recherche.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Institute of Parasitology, McGill University, 21,111 Lakeshore Rd., Ste-Anne-de-Bellevue, Quebec H9X 3V9, Canada. Tel.: 514 398 8137; Fax: 514 398 7857; E-mail: Elias.Georges@McGill.CA
Published, JBC Papers in Press, January 4, 2001, DOI 10.1074/jbc.M009782200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: P-gp, P-glycoprotein; MDR, multidrug resistance; MRP, multidrug resistance protein; PAGE, polyacrylamide gel electrophoresis; Rh123, rhodamine 123; IAARh123, iodoaryl azido-Rh123; HA, hemagglutinin A; mAb, monoclonal antibody; MSD, membrane-spanning domain; NBD, nucleotide binding domain; TM, transmembrane domain; IACI, N-2-hydroxy-4-azido-5-iodophenylacetyldihydro-7-chloro-8-amino-cin-choanan-9R-ol.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Bradley, G., and Ling, V. (1994) Cancer Metastasis Rev. 13, 223-233[Medline] [Order article via Infotrieve] |
2. | Cole, S., and Deeley, R. (1998) Bioessays 20, 931-940[CrossRef][Medline] [Order article via Infotrieve] |
3. | Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., var der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., Berns, A. J. M., and Borst, P. (1994) Cell 77, 491-502[Medline] [Order article via Infotrieve] |
4. | Wijnholds, J., Evers, R., van Leusden, M. R., Mol, C. A., Zaman, G. J., Mayer, U., Beijnen, J. H., van der Valk, M., Krimpenfort, P., and Borst, P. (1997) Nat. Med. 3, 1275-1279[Medline] [Order article via Infotrieve] |
5. | Cole, S. P. C., Bharswaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. (1992) Science 258, 1650-1654[Medline] [Order article via Infotrieve] |
6. | Zaman, G. J. R., and Borst, P. (1996) in Multidrug Resistance in Cancer Cells (Gupta, S. , and Tsuruo, T., eds) , pp. 95-107, John Wiley & Sons, Inc., West Sussex UK |
7. | Evers, R., Cnubben, N. H., Wijnholds, J., van Deemter, L., van Bladeren, P. J., and Borst, P. (1997) FEBS Lett. 419, 112-116[CrossRef][Medline] [Order article via Infotrieve] |
8. | Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G., and Keppler, D. (1996) Cancer Res. 56, 988-994[Abstract] |
9. |
Leier, I.,
Jedlitschky, G.,
Buchholz, U.,
Cole, S. P.,
Deeley, R. G.,
and Keppler, D.
(1994)
J. Biol. Chem.
269,
27807-27810 |
10. |
Loe, D. W.,
Stewart, R. K.,
Massey, T. E.,
Deeley, R. G.,
and Cole, S. P.
(1997)
Mol. Pharmacol.
51,
1034-1041 |
11. | Shen, H., Paul, S., Breuninger, L. M., Ciaccio, P. J., Laing, N. M., Helt, M., Tew, K. D., and Kruh, G. D. (1996) Biochemistry 35, 5719-5726[CrossRef][Medline] [Order article via Infotrieve] |
12. | Ishikawa, T. (1992) Trends Biochem. Sci. 17, 463-468[CrossRef][Medline] [Order article via Infotrieve] |
13. | Leier, I., Jedlitschky, G., Buchholz, U., Center, M., Cole, S., Deeley, R., and Keppler, D. (1996) Biochem. J. 314, 433-437[Medline] [Order article via Infotrieve] |
14. | Klein, I., Sarkadi, B., and Varadi, A. (1999) Biochim. Biophys. Acta 1461, 237-262[Medline] [Order article via Infotrieve] |
15. |
Bakos, E.,
Hegedus, T.,
Hollo, Z.,
Welker, E.,
Tusnady, G. E.,
Zaman, G. J.,
Flens, M. J.,
Varadi, A.,
and Sarkadi, B.
(1996)
J. Biol. Chem.
271,
12322-12326 |
16. |
Hipfner, D. R.,
Almquist, K. C.,
Leslie, E. M.,
Gerlach, J. H.,
Grant, C. E.,
Deeley, R. G.,
and Cole, S. P. C.
(1997)
J. Biol. Chem.
272,
23623-23630 |
17. |
Kast, C.,
and Gros, P.
(1997)
J. Biol. Chem.
272,
26479-26487 |
18. | Loo, T., and Clarke, D. (1999) Biochemistry 38, 5124-5129[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Bakos, E.,
Evers, R.,
Szakacs, G.,
Tusnady, G. E.,
Welker, E.,
Szabo, K.,
de Hass, M.,
van Deemter, L.,
Borst, P.,
Varadi, A.,
and Sarkadi, B.
(1998)
J. Biol. Chem.
273,
32167-32175 |
20. |
Gao, M.,
Yamazaki, M.,
Loe, D.,
Westlake, C.,
Grant, C.,
Cole, S.,
and Deeley, R.
(1998)
J. Biol. Chem.
273,
10733-10740 |
21. | Shapiro, A., and Ling, V. (1998) Acta Physiol. Scand. Suppl. 643, 227-234[CrossRef][Medline] [Order article via Infotrieve] |
22. | Rao, U. S., and Scarborough, G. A. (1994) Mol. Pharmacol. 45, 773-776[Abstract] |
23. |
Loe, D. W.,
Almquist, K. C.,
Deeley, R. G.,
and Cole, S. P.
(1996)
J. Biol. Chem.
271,
9675-9682 |
24. | Loe, D., Deeley, R., and Cole, S. (1998) Cancer Res. 58, 5130-5136[Abstract] |
25. | Rappa, G., Lorico, A., Flavell, R. A., and Sartorelli, A. C. (1997) Cancer Res. 57, 5232-5237[Abstract] |
26. |
Renes, J.,
de Vries, E. G.,
Nienhuis, E. F.,
Jansen, P. L.,
and Muller, M.
(1999)
Br. J. Pharmacol.
126,
681-688 |
27. | Daoud, R., Desneves, J., Deady, L. W., Tilley, L., Scheper, R. J., Gros, P., and Georges, E. (2000) Biochemistry 39, 6094-6102[CrossRef][Medline] [Order article via Infotrieve] |
28. | Daoud, R., Kast, K., Gros, P., and Georges, E. (2000) Biochemistry 39, 15344-15352[CrossRef][Medline] [Order article via Infotrieve] |
29. | Vezmar, M., and Georges, E. (1998) Biochem. Pharmacol. 56, 733-742[CrossRef][Medline] [Order article via Infotrieve] |
30. | Vezmar, M., Deady, L. W., Tilley, L., and Georges, E. (1997) Biochem. Biophys. Res. Commun. 241, 104-111[CrossRef][Medline] [Order article via Infotrieve] |
31. | Vezmar, M., and Georges, E. (2000) Biochem. Pharmacol. 59, 1245-1252[CrossRef][Medline] [Order article via Infotrieve] |
32. | Kast, C., and Gros, P. (1998) Biochemistry 37, 2305-2313[CrossRef][Medline] [Order article via Infotrieve] |
33. |
Lowry, O. H.,
Rosebrough, N. J.,
Farr, A. L.,
and Randall, R. J.
(1951)
J. Biol. Chem.
193,
265-275 |
34. | Cleveland, D. W., Fischer, S. G., Kirschner, M. W., and Laemmli, U. K. (1977) J. Biol. Chem. 252, 1102-1106[Abstract] |
35. | Georges, E., Zhang, J.-T., and Ling, L. (1991) J. Cell. Physiol. 148, 479-484[Medline] [Order article via Infotrieve] |
36. | Fairbanks, G., Steck, T. L., and Wallach, D. F. H. (1971) Biochemistry 10, 2606-2617[Medline] [Order article via Infotrieve] |
37. | Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad Sci. U. S. A. 76, 4350-4354[Abstract] |
38. | Hipfner, D., Almquist, K., Stride, B., Deeley, R., and Cole, S. (1996) Cancer Res. 56, 3307-3314[Abstract] |
39. | Hipfner, D. R., Deeley, R. G., and Cole, S. P. (1999) Biochim. Biophys. Acta 1461, 359-376[Medline] [Order article via Infotrieve] |
40. |
Stride, B. D.,
Cole, S. P. C.,
and Deeley, R. G.
(1999)
J. Biol. Chem.
274,
22877-22883 |
41. | Kajiji, S., Talbot, F., Grizzuti, K., Van Dyke-Phillips, V., Agresti, M., Safa, A. R., and Gros, P. (1993) Biochemistry 32, 4185-4194[Medline] [Order article via Infotrieve] |
42. |
Greenberger, L. M.
(1993)
J. Biol. Chem.
268,
11417-11425 |
43. |
Loo, T.,
and Clarke, D.
(1997)
J. Biol. Chem.
272,
31945-31948 |
44. |
Dey, S.,
Ramachandra, M.,
Pastan, I.,
Gottesman, M. M.,
and Ambudkar, S. V.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10594-10599 |
45. |
Shapiro, A.,
Fox, K.,
Lam, P.,
and Ling, V.
(1999)
Eur. J. Biochem.
259,
841-850 |
46. | Versantvoort, C. H., Broxterman, H. J., Bagrij, T., Scheper, R. J., and Twentyman, P. R. (1995) Br. J. Cancer 72, 82-89[Medline] [Order article via Infotrieve] |
47. | Feller, N., Kuiper, C. M., Lankelma, J., Ruhdal, J. K., Scheper, R. J., Pinedo, H. M., and Broxterman, H. J. (1995) Br. J. Cancer 72, 543-549[Medline] [Order article via Infotrieve] |
48. | Draper, M. P., Martell, R. L., and Levy, S. B. (1997) Eur. J. Biochem. 243, 219-224[Abstract] |